Table 2.

Basic characteristics of RNS studies included.

Author	Year	Study type	N	Age (mean ± SD)	Epilepsy duration (years)	Follow up (months)	Seizure reduction	Responder rate	Adverse event
Anderson	2008	Prospective	5	34 ± 10.9	NAa	23.2 ± 1.3	0.51	0.80	0
Heck	2014	RCTb	191	34.9 ± 11.5	20.0 ± 11.2	24	0.53	0.55	0.03
Chen	2017	Retrospective	7	24	NA	6	0.55 ± 0.33	0.71	0.14
Geller	2017	Prospective	111	37.3 ± 11.3	19.8 ± 12.7	73.2 ± 7.6	0.67 ± 0.46	0.65	0.12
Kerolus	2017	Prospective	8	44.6 ± 12.1	NA	9.6 ± 7.2	0.74 ± 0.16	1	NA
Jobst	2017	RCT	126	30.4 ± 10.1	19.5 ± 10.2	73.2	0.58 ± 0.63	0.55	0.07
Young	2018	Retrospective	9	34.4	NA	NA	0.4	0.75	NA
Chan	2019	Retrospective	8	44.8	15.6	14.4	0.69 ± 0.24	0.63	NA
Nune	2019	Retrospective	8	45.5 ± 10.4	15.1 ± 6	NA	0.85 ± 0.03	0.88	NA
Sisterson	2020	Retrospective	12	35.6 ± 11.9	18.5 ± 10.4	21.5 ± 10.4	0.67	0.42	NA
Wang	2020	Retrospective	12	39.2 ± 12.1	12.8 ± 9.4	43.6 ± 39.1	0.58 ± 0.39	0.67	0.13
Nunna	2020	Retrospective	10	44.6 ± 7.1	21.6	50.4 ± 11.4	0.44 ± 0.34	0.40	0.10
Razavi	2020	Retrospective	150	39	20	27.6	0.74 ± 0.34	0.84	0.11
Tran	2020	Retrospective	10	36	NA	NA	0.81 ± 0.09	1	0.2
Karas	2020	Retrospective	10	40	15	7.5	0.26 ± 0.55	0.38	0
Burdette	2020	Retrospective	7	33.4 ± 9.5	NA	16.8	0.8 ± 0.29	0.86	0.22
Ma	2020	Retrospective	30	NA	14.2 ± 10.3	21 ± 11.6	0.63 ± 0.33	0.70	0
McDermott	2021	Retrospective	5	35	NA	16.8	0.88 ± 0.17	1	NA
Zawar	2021	Retrospective	55	35.1 ± 12.9	19.5 ± 12.6	38 (6–144)	0.50 ± 0.36	0.55	NA
Brown	2022	Retrospective	64	36.0 ± 11.8	NA	27.6	0.39 ± 1.06	0.67	0.26
Zermeno	2022	Retrospective	30	39	18	19.2	0.5 ± 0.39	0.56	0
Chen	2022	Retrospective	9	40 ± 16.3	11.3 ± 6.73	31.2	0.39 ± 0.37	0.44	NA
Ho	2022	Retrospective	13	38.3 ± 10.4	25.2 ± 12.9	57.6 ± 13.2	0.71 ± 0.19	0.77	0

^aNA represent not available.

^bRCT represent randomized controlled study.